Danielle Brill
Stock Analyst at Raymond James
(1.07)
# 2,707
Out of 4,413 analysts
53
Total ratings
29.79%
Success rate
-14.49%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Downgrades: Outperform | $40 | $28.53 | +40.20% | 4 | Apr 1, 2024 | |
| ARGX argenx SE | Maintains: Strong Buy | $580 → $520 | $383.34 | +35.65% | 6 | Dec 21, 2023 | |
| BIIB Biogen | Upgrades: Outperform | $283 | $216.13 | +30.94% | 1 | Dec 7, 2023 | |
| PASG Passage Bio | Maintains: Outperform | $9 → $5 | $1.35 | +270.37% | 5 | Nov 14, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $135 → $145 | $143.03 | +1.38% | 4 | Nov 1, 2023 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $26 → $27 | $30.27 | -10.80% | 6 | Nov 1, 2023 | |
| IMVT Immunovant | Upgrades: Outperform | $40 | $28.52 | +40.25% | 3 | Sep 27, 2023 | |
| PTCT PTC Therapeutics | Downgrades: Underperform | n/a | $34.16 | - | 8 | Sep 18, 2023 | |
| QURE uniQure | Maintains: Outperform | $56 → $50 | $4.57 | +994.09% | 4 | Aug 2, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $1.17 | - | 4 | Jun 27, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $52 | $42.49 | +22.38% | 1 | Oct 19, 2022 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $402.14 | - | 1 | Jul 1, 2021 | |
| AGIO Agios Pharmaceuticals | Initiates: Market Perform | n/a | $33.66 | - | 1 | Jul 1, 2021 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Outperform | n/a | $17.05 | - | 2 | Mar 9, 2021 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $130.90 | - | 2 | Jan 8, 2021 | |
| SAGE Sage Therapeutics | Initiates: Buy | n/a | $13.28 | - | 1 | May 16, 2017 |
Disc Medicine
Apr 1, 2024
Downgrades: Outperform
Price Target: $40
Current: $28.53
Upside: +40.20%
argenx SE
Dec 21, 2023
Maintains: Strong Buy
Price Target: $580 → $520
Current: $383.34
Upside: +35.65%
Biogen
Dec 7, 2023
Upgrades: Outperform
Price Target: $283
Current: $216.13
Upside: +30.94%
Passage Bio
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $1.35
Upside: +270.37%
Neurocrine Biosciences
Nov 1, 2023
Maintains: Outperform
Price Target: $135 → $145
Current: $143.03
Upside: +1.38%
Harmony Biosciences Holdings
Nov 1, 2023
Maintains: Outperform
Price Target: $26 → $27
Current: $30.27
Upside: -10.80%
Immunovant
Sep 27, 2023
Upgrades: Outperform
Price Target: $40
Current: $28.52
Upside: +40.25%
PTC Therapeutics
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $34.16
Upside: -
uniQure
Aug 2, 2023
Maintains: Outperform
Price Target: $56 → $50
Current: $4.57
Upside: +994.09%
FibroGen
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
Xenon Pharmaceuticals
Oct 19, 2022
Initiates: Outperform
Price Target: $52
Current: $42.49
Upside: +22.38%
Vertex Pharmaceuticals
Jul 1, 2021
Initiates: Market Perform
Price Target: n/a
Current: $402.14
Upside: -
Agios Pharmaceuticals
Jul 1, 2021
Initiates: Market Perform
Price Target: n/a
Current: $33.66
Upside: -
ACADIA Pharmaceuticals
Mar 9, 2021
Downgrades: Outperform
Price Target: n/a
Current: $17.05
Upside: -
Sarepta Therapeutics
Jan 8, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $130.90
Upside: -
Sage Therapeutics
May 16, 2017
Initiates: Buy
Price Target: n/a
Current: $13.28
Upside: -